ID | Age | Sex | Diagnosis | Additional treatments | Baseline | After infliximab treatment | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DAS28 | ESR (mm) | CRP (mg/L) | TJC | SJC | DAS28 | ESR (mm) | CRP (mg/L) | TJC | SJC | |||||
1 | 43 | F | RA+ | M, N, Pa | 3.80 | 18 | 5.4 | 1 | 1 | 3.82 | 15 | ND | 1 | 0 |
2 | 34 | F | RA− | M, N, Pa | 4.77 | 18 | 3.0 | 4 | 4 | 4.39 | 29 | 2.3 | 4 | 0 |
3 | 74 | F | RA− | M, Pr, Pa | 7.50 | 90 | 93.3 | 13 | 12 | 6.67 | 50 | 43.3 | 13 | 11 |
4 | 35 | F | JCA | M, Pr, N | 4.10 | 11 | 7.6 | 7 | 4 | 2.96 | 10 | 7.4 | 4 | 0 |
5 | 41 | F | JCA | M, Pr, Pa | 2.35 | 10 | 4.0 | 0 | 0 | ND | ND | 0.5 | ND | ND |
6 | 26 | F | AS | M, Pr, N | ND | 90 | 56.5 | ND | ND | ND | 24 | 1.7 | ND | ND |
7 | 52 | F | PsA | M, N | 6.34 | 90 | 78.8 | 6 | 4 | 4.73 | 48 | ND | 4 | 2 |
Patients without paired CSF samples | ||||||||||||||
8 | 31 | F | RA+ | M, N, Pa | ND | 41 | 19.8 | 15 | 15 | ND | 12 | 0.5 | ND | ND |
9 | 51 | F | RA+ | M, A | 5.94 | 30 | 15.6 | 12 | 3 | ND | 11 | 1.6 | 1 | 2 |
10 | 61 | F | PsA | M, N, Pa | 5.51 | 63 | 28.6 | 2 | 4 | ND | ND | 0.9 | 0 | 0 |